Traditional means to identify the physiological severity of arterial disease are hampered by their inability to identify atheroma extent and composition. New techniques that identify atheroma in vivo are being developed, however, accurate methodologies for atheroma characterization are hampered, due to the heterogeneous nature of the disease process. Novel acoustic targeting and highlighting agents, such as liposomes, may overcome these problems. Liposomes are phospholipid vesicles enclosing an aqueous space. We have developed a unique methodology that, by process and composition, provides acoustic characteristics of liposomes. This formulation allows modification for antibody conjugation and therapeutic drug incorporation. Preliminary work by this group has been centered on the optimization of formulation, optimization of conjugation, and development of in vitro and in vivo quantitation techniques. This proposal describes a series of protocols to optimize highlighting and enhancing We plan to investigate the potential of these formulations to aid other imaging modalities as atheroma enhancement agents. Our long term goals are to determine, quantitate, and characterize the stage, extent, and physiologic severity of atherosclerosis and allow directed therapy to improve physiologic flow following intervention.
This proposal seeks to develop a stable formulation (echogenic immunoliposomes) that has the ability to highlight, characterize, and quantify the progression of atherosclerosis.
|Kee, Patrick H; Kim, Hyunggun; Huang, Shaoling et al. (2014) Nitric oxide pretreatment enhances atheroma component highlighting in vivo with intercellular adhesion molecule-1-targeted echogenic liposomes. Ultrasound Med Biol 40:1167-76|
|Raymond, Jason L; Haworth, Kevin J; Bader, Kenneth B et al. (2014) Broadband attenuation measurements of phospholipid-shelled ultrasound contrast agents. Ultrasound Med Biol 40:410-21|
|Bader, Kenneth B; Holland, Christy K (2013) Gauging the likelihood of stable cavitation from ultrasound contrast agents. Phys Med Biol 58:127-44|
|Radhakrishnan, Kirthi; Bader, Kenneth B; Haworth, Kevin J et al. (2013) Relationship between cavitation and loss of echogenicity from ultrasound contrast agents. Phys Med Biol 58:6541-63|
|Sutton, Jonathan T; Haworth, Kevin J; Pyne-Geithman, Gail et al. (2013) Ultrasound-mediated drug delivery for cardiovascular disease. Expert Opin Drug Deliv 10:573-92|
|Kim, Hyunggun; Kee, Patrick H; Rim, Yonghoon et al. (2013) Nitric oxide improves molecular imaging of inflammatory atheroma using targeted echogenic immunoliposomes. Atherosclerosis 231:252-60|
|Peng, Tao; Britton, George L; Kim, Hyunggun et al. (2013) Therapeutic time window and dose dependence of xenon delivered via echogenic liposomes for neuroprotection in stroke. CNS Neurosci Ther 19:773-84|
|Kopechek, Jonathan A; Haworth, Kevin J; Radhakrishnan, Kirthi et al. (2013) The impact of bubbles on measurement of drug release from echogenic liposomes. Ultrason Sonochem 20:1121-30|
|Kopechek, Jonathan A; Haworth, Kevin J; Raymond, Jason L et al. (2011) Acoustic characterization of echogenic liposomes: frequency-dependent attenuation and backscatter. J Acoust Soc Am 130:3472-81|
|Laing, Susan T; Moody, Melanie; Smulevitz, Beverly et al. (2011) Ultrasound-enhanced thrombolytic effect of tissue plasminogen activator-loaded echogenic liposomes in an in vivo rabbit aorta thrombus model--brief report. Arterioscler Thromb Vasc Biol 31:1357-9|
Showing the most recent 10 out of 24 publications